Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
70 participants
INTERVENTIONAL
2024-03-31
2024-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Wearable Dark-adaptometer in Normal Adult Healthy Volunteers
NCT02674425
Quality of Life Measures in Patients With Retinal Degeneration
NCT02814435
In Depth Observational Clinical Trial Of Retinitis Pigmentosa Patients
NCT05849987
Subthreshold Micropulse Laser Therapy (SML) in Retinitis Pigmentosa
NCT07088705
Visual and Functional Assessment in Low Vision Patients
NCT01876147
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
70 adults with typical RP in which the underlying genetic cause is known will be recruited from Moorfields Eye Hospital genetics service.
Following informed consent, participants will be invited for a baseline study visit.
At a baseline visit, prior to any light exposure (day 0), participants will undergo Logarithm of the Minimum Angle of Resolution (LogMAR) visual acuity (VA) and CCT measurements performed by an experienced technician according to dedicated standard operating procedures. The order of testing will be as follows:
* Study eye: LogMAR VA
* Study eye: CCT (Tritan and Protan)
After baseline assessments have been completed, participants will be randomised to the intervention (n=35) or control group (n=35) by a study nurse. All other study team members will be masked to group allocation.
The intervention group will be provided with a coloured torch and instructed to apply it to their study eye for 3 minutes at home each morning between 8 - 10 am for 28 days. The control group will be provided with a different coloured torch and will be instructed to follow the same protocol. The specific colours have not be disclosed here to protect masking of the study. Participants will be asked to complete a paper diary each day to record whether light was applied, the time and duration of the application and the eye to which light was applied.
The end of trial visit will be scheduled on day 28 (+7 days). Participants will undergo LogMAR VA and CCT measurements by an experienced technician according to standard operating procedures (SOP). The order of testing will be as follows:
* Study eye: LogMAR VA
* Study eye: CCT (Tritan and Protan)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Coloured light 1 group
Coloured light 1 group will be provided with a coloured-light torch and instructed to apply it to their study eye for 3 minutes at home each morning between 8 - 10 am for 28 days.
Coloured-light torch
Participant administered, at-home, 3-minute daily morning application (between 8 - 10am) of a coloured-light torch to the study eye.
Coloured light 2 group
Coloured light 2 group will be provided with a different coloured-light torch and instructed to apply it to their study eye for 3 minutes at home each morning between 8 - 10 am for 28 days.
Different coloured-light torch
Participant administered, at-home, 3-minute daily morning application (between 8 - 10am) of a different coloured-light torch to the study eye.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Coloured-light torch
Participant administered, at-home, 3-minute daily morning application (between 8 - 10am) of a coloured-light torch to the study eye.
Different coloured-light torch
Participant administered, at-home, 3-minute daily morning application (between 8 - 10am) of a different coloured-light torch to the study eye.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Typical RP where the underlying genetic cause is known. This may include PRPF31, PRPF8, SNRNP200, RHO, RP1 \[autosomal dominant\] and USH2A, EYS \[autosomal recessive\]
* VA of 0.30 LogMAR (6/12) or better in the study eye
* Preserved foveal structure defined by intact outer retinal (ellipsoid zone) at the fovea on Optical Coherence Tomography (OCT) and a hyperfluorescent ring within the temporal vascular arcades on Fundus Autofluorescence (FAF) in the study eye
* Willing and able to provide written informed consent
Exclusion Criteria
* Concurrent and/or recent involvement in other research that is likely to interfere with the intervention within 6 months of study enrolment
* Unwilling or able to provide written informed consent.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University College, London
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hannah Dunbar, PhD
Role: PRINCIPAL_INVESTIGATOR
UCL Institute of Ophthalmology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Moorfields Eye Hospital NHS Foundation Trust
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Hannah Dunbar, PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
161090
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.